These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prescription-drug coupons--no such thing as a free lunch. Ross JS; Kesselheim AS N Engl J Med; 2013 Sep; 369(13):1188-9. PubMed ID: 23984672 [No Abstract] [Full Text] [Related]
3. Lost sleep... Pontious JM J Okla State Med Assoc; 2002 Aug; 95(8):523. PubMed ID: 12185985 [No Abstract] [Full Text] [Related]
5. Possible anticompetitive agreements between brand, generic companies to be studied. Landis NT Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691 [No Abstract] [Full Text] [Related]
6. A few specialty drug prices fall--all generics. Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766 [No Abstract] [Full Text] [Related]
8. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules. Scott Morton F Rand J Econ; 1997; 28(2):269-90. PubMed ID: 11794358 [TBL] [Abstract][Full Text] [Related]
9. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs. Cahn LJ Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372 [No Abstract] [Full Text] [Related]
10. Will Courts Allow States to Regulate Drug Prices? Robertson C N Engl J Med; 2018 Sep; 379(11):1000-1002. PubMed ID: 30088965 [No Abstract] [Full Text] [Related]
11. [Blocking of generic drugs must be fought]. Kringlen E Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2032. PubMed ID: 24129531 [No Abstract] [Full Text] [Related]
12. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry. Sinha MS; Curfman GD; Carrier MA JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104 [No Abstract] [Full Text] [Related]
14. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care. Work DR; Domino ME N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614 [No Abstract] [Full Text] [Related]
15. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Pavenik N Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303 [TBL] [Abstract][Full Text] [Related]
16. Drug price divergence in Europe: regulatory aspects. Huttin C Health Aff (Millwood); 1999; 18(3):245-9. PubMed ID: 10388221 [No Abstract] [Full Text] [Related]
18. Are patent expirations the answer to improving patient adherence? Klepser DG Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495 [No Abstract] [Full Text] [Related]
19. A guide for paying less for prescription drugs. Johns Hopkins Med Lett Health After 50; 2003 Sep; 15(7):4-5. PubMed ID: 14533592 [No Abstract] [Full Text] [Related]
20. [The patient is without rights if the drug company is not included in the pharmaceutical insurance]. Eklund J Lakartidningen; 2013 Nov 6-12; 110(45):2005. PubMed ID: 24364190 [No Abstract] [Full Text] [Related] [Next] [New Search]